Relmada Therapeutics Inc. (Nasdaq: RLMD) will halt its Phase 3 studies of depression treatment REL-1017 following a data monitoring committee evaluation, sending the company searching for strategic alternatives. The late-stage biotechnology company will discontinue both the Reliance II and Relight Phase 3 studies while continuing development of REL-P11, its modified …